Prestige Consumer Healthcare (NYSE:PBH) Stock Bumped Down to Hold by Zacks Research

Zacks Research downgraded shares of Prestige Consumer Healthcare (NYSE:PBH) from a strong-buy rating to a hold rating in a research report report published on Thursday morning,Zacks reports.

Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 22nd. One analyst has rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of “Hold” and a consensus price target of $67.67.

Prestige Consumer Healthcare Stock Up 0.7%

Shares of PBH opened at $49.08 on Thursday. Prestige Consumer Healthcare has a 52 week low of $42.62 and a 52 week high of $71.07. The stock has a market capitalization of $2.33 billion, a price-to-earnings ratio of 13.75, a PEG ratio of 1.53 and a beta of 0.34. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.99 and a current ratio of 3.23. The stock has a fifty day moving average of $48.54 and a 200-day moving average of $54.20.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.09. The company had revenue of $265.71 million for the quarter, compared to the consensus estimate of $253.02 million. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%. Prestige Consumer Healthcare’s revenue for the quarter was up 6.5% on a year-over-year basis. During the same quarter last year, the business posted $0.90 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. As a group, sell-side analysts anticipate that Prestige Consumer Healthcare will post 4.56 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Great Lakes Advisors LLC bought a new position in Prestige Consumer Healthcare during the 2nd quarter worth approximately $2,981,000. Bessemer Group Inc. lifted its position in shares of Prestige Consumer Healthcare by 20.9% in the 1st quarter. Bessemer Group Inc. now owns 374,691 shares of the company’s stock worth $22,207,000 after purchasing an additional 64,760 shares during the period. Rice Hall James & Associates LLC acquired a new position in shares of Prestige Consumer Healthcare in the 2nd quarter worth approximately $32,602,000. Corient Private Wealth LP acquired a new position in shares of Prestige Consumer Healthcare in the 2nd quarter worth approximately $1,202,000. Finally, Jupiter Topco LLC bought a new stake in shares of Prestige Consumer Healthcare in the 2nd quarter valued at $1,068,000. 99.95% of the stock is currently owned by institutional investors and hedge funds.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc (NYSE: PBH) is a consumer healthcare company that develops, acquires, markets and distributes over-the-counter health and wellness products. Its portfolio is focused on established brands designed to address everyday healthcare needs, including digestive health, eye and ear care, oral care, pain relief, cold and allergy symptoms, feminine care and dermatological conditions.

The company’s brands include Dramamine and Bonine for motion-sickness relief; BC and Goody’s for pain relief; Clear Eyes and Murine for eye and ear care; Chloraseptic for sore-throat relief; Compound W for wart removal; Fleet for gastrointestinal health; and Summer’s Eve for feminine care.